Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?

“…Information was available from 12 systematic reviews [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], 11 of which were Cochrane reviews, covering drug interventions and interventions including behavioural counselling, group therapy, and exercise programmes, as well as nurse or doctor interventions. Data were available on over 127,000 participants with cessation rates at six months or longer, with the bulk from reviews of nicotine replacement therapy (NRT), physical intervention, self-help, nursing interventions and bupropion.…”

Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?

“…Information was available from 12 systematic reviews [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], 11 of which were Cochrane reviews, covering drug interventions and interventions including behavioural counselling, group therapy, and exercise programmes, as well as nurse or doctor interventions. Data were available on over 127,000 participants with cessation rates at six months or longer, with the bulk from reviews of nicotine replacement therapy (NRT), physical intervention, self-help, nursing interventions and bupropion.…”

Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial

“…The review of preclinical and human studies concluded that while cannabinoid CB 1 receptor antagonism may have potential in smoking cessation, efficacy would be moderate and that this class of drugs would probably not ameliorate nicotine withdrawal symptoms (Le Foll et al, 2008). The Cochrane meta-analysis concluded that the odds of quitting were increased by about 1.61 (95% CI, 1.12–3.20) (Cahill and Ussher, 2007). A similar significant OR has been found in the pooled analysis of three short-term trials (Le Foll et al, 2008).…”

“…Other limitations include lack of testing of a higher dose of surinabant, e.g. 20 mg, as 20 mg of rimonabant has shown efficacy for cessation (Cahill and Ussher, 2007). Also, detailed mood questionnaires were not administered, limiting the understanding of adverse events that may be related to surinabant.…”

Meta‐analysis of repeated measures study designs

“…However, the interpretation and clinical importance of the resultant pooled estimate may be limited as the primary studies may have different first/final time-points. Examples of this approach can be seen in Spittle et al [36] and Cahill et al [37] who both combine study estimates at the final time-point.…”

Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?

“…Information was available from 12 systematic reviews [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], 11 of which were Cochrane reviews, covering drug interventions and interventions including behavioural counselling, group therapy, and exercise programmes, as well as nurse or doctor interventions. Data were available on over 127,000 participants with cessation rates at six months or longer, with the bulk from reviews of nicotine replacement therapy (NRT), physical intervention, self-help, nursing interventions and bupropion.…”

Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial

“…The review of preclinical and human studies concluded that while cannabinoid CB 1 receptor antagonism may have potential in smoking cessation, efficacy would be moderate and that this class of drugs would probably not ameliorate nicotine withdrawal symptoms (Le Foll et al, 2008). The Cochrane meta-analysis concluded that the odds of quitting were increased by about 1.61 (95% CI, 1.12–3.20) (Cahill and Ussher, 2007). A similar significant OR has been found in the pooled analysis of three short-term trials (Le Foll et al, 2008).…”

“…Other limitations include lack of testing of a higher dose of surinabant, e.g. 20 mg, as 20 mg of rimonabant has shown efficacy for cessation (Cahill and Ussher, 2007). Also, detailed mood questionnaires were not administered, limiting the understanding of adverse events that may be related to surinabant.…”

Meta‐analysis of repeated measures study designs

“…However, the interpretation and clinical importance of the resultant pooled estimate may be limited as the primary studies may have different first/final time-points. Examples of this approach can be seen in Spittle et al [36] and Cahill et al [37] who both combine study estimates at the final time-point.…”

Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?

“…Information was available from 12 systematic reviews [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ], 11 of which were Cochrane reviews, covering drug interventions and interventions including behavioural counselling, group therapy, and exercise programmes, as well as nurse or doctor interventions. Data were available on over 127,000 participants with cessation rates at six months or longer, with the bulk from reviews of nicotine replacement therapy (NRT), physical intervention, self-help, nursing interventions and bupropion.…”

Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial

“…The review of preclinical and human studies concluded that while cannabinoid CB 1 receptor antagonism may have potential in smoking cessation, efficacy would be moderate and that this class of drugs would probably not ameliorate nicotine withdrawal symptoms (Le Foll et al, 2008). The Cochrane meta-analysis concluded that the odds of quitting were increased by about 1.61 (95% CI, 1.12–3.20) (Cahill and Ussher, 2007). A similar significant OR has been found in the pooled analysis of three short-term trials (Le Foll et al, 2008).…”

“…Other limitations include lack of testing of a higher dose of surinabant, e.g. 20 mg, as 20 mg of rimonabant has shown efficacy for cessation (Cahill and Ussher, 2007). Also, detailed mood questionnaires were not administered, limiting the understanding of adverse events that may be related to surinabant.…”

Meta‐analysis of repeated measures study designs

“…However, the interpretation and clinical importance of the resultant pooled estimate may be limited as the primary studies may have different first/final time-points. Examples of this approach can be seen in Spittle et al [36] and Cahill et al [37] who both combine study estimates at the final time-point.…”